Minnesota Clinical Study Center
Minnesota Clinical Study Center
New Brighton, Minnesota, United States13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2/3 Efficacy and Safety of PP405 in Adult Males | Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, androgenetic alopecia, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-07 | NCT07819435 | |
| A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06095115 | |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06934226 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06095102 | |
| Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis | Prurigo Nodularis (PN) | Recruiting | Phase 2 | 2026-09-14 | NCT07236099 | |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) | DNA Virus Infections, Infections, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, common wart, human papilloma virus infection, skin disorder, skin disorder caused by infection, viral infectious disease | Recruiting | Phase 3 | 2026-09-03 | NCT07637734 | |
| Evaluate RLS-1496 Topical Cream for Actinic Keratosis | Skin and Connective Tissue Diseases, actinic keratosis, keratosis, neoplasm, precancerous condition, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-12 | NCT07340697 | |
| A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-06-02 | NCT06550076 | |
| Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | Skin and Connective Tissue Diseases, actinic keratosis, keratosis, neoplasm, precancerous condition, skin disorder | Recruiting | Phase 3 | 2026-04-22 | NCT07144852 | |
| Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | Skin and Connective Tissue Diseases, actinic keratosis, keratosis, neoplasm, precancerous condition, skin disorder | Recruiting | Phase 3 | 2026-04-22 | NCT07144345 | |
| A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations | Cutaneous Venous Malformations | Active, not recruiting | Phase 2 | 2026-03-27 | NCT06653842 | |
| SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Lymphatic Abnormalities, Neoplasm, Lymphatic Tissue, Neoplasms by Histologic Type, cardiovascular disorder, lymphangioma, lymphatic system disorder, microcystic lymphatic malformation, neoplasm, vascular malformation | Active, not recruiting | Phase 3 | 2026-03-27 | NCT06239480 | |
| A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita | Abnormalities, Multiple, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, ectodermal dysplasia syndrome, hereditary disease, hereditary skin disorder, nail disorder, pachyonychia congenita, skin disorder | Recruiting | Phase 3 | 2022-12-09 | NCT05643872 |